ASND in the 13F filings
Ascendis Pharma A · CUSIPs 04351P101, K08588103
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 27
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 9 listed it in both
- Shares listed
- 17,758,047
- combined, among listed positions
- Reported value
- $4.7bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 19 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,068,158.
Managers listing ASND in Q2 2026
27 of 27 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdnew position · 3,648,772 shares now+3,648,772
- Jane Street Group LLCnew position · 187,141 shares now+187,141
- Neuberger Berman Group LLCnew position · 142,705 shares now+142,705
- Citadel Advisors LLCnew position · 137,889 shares now+137,889
- Walleye Capital LLCexisting position · 126,005 shares now+125,968
Reductions
- Artisan Partners LPexisting position · 2,634,024 shares now-596,164
- T. Rowe Price Associates Incexisting position · 1,122,529 shares now-407,816
- Fidelity (FMR LLC)existing position · 3,545,575 shares now-331,026
- Wellington Management Group LLPexisting position · 1,548,636 shares now-208,997
- Voloridge Investment Management LLCexisting position · 29,303 shares now-84,972
New positions and exits
New (9)
Exited (2)
- Polen Capital Management LLCwas $414k
- AQR Capital Management LLCwas $352k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2017 | 1 | $2.1m | n.a. | n.a. |
| Q3 2017 | 2 | $4.7m | n.a. | n.a. |
| Q4 2017 | 1 | $4.8m | n.a. | n.a. |
| Q1 2018 | 6 | $362m | n.a. | n.a. |
| Q2 2018 | 4 | $310m | n.a. | n.a. |
| Q3 2018 | 3 | $359m | n.a. | n.a. |
| Q4 2018 | 4 | $638m | n.a. | n.a. |
| Q1 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q2 2019 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q4 2019 | 12 | $2.8bn | n.a. | n.a. |
| Q1 2020 | 9 | $2.3bn | n.a. | n.a. |
| Q2 2020 | 8 | $3.2bn | n.a. | n.a. |
| Q3 2020 | 9 | $4.1bn | n.a. | n.a. |
| Q4 2020 | 12 | $4.5bn | n.a. | n.a. |
| Q1 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q2 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q3 2021 | 10 | $4.5bn | n.a. | n.a. |
| Q4 2021 | 11 | $3.7bn | n.a. | n.a. |
| Q1 2022 | 10 | $3.3bn | n.a. | n.a. |
| Q2 2022 | 9 | $2.5bn | n.a. | n.a. |
| Q3 2022 | 12 | $2.7bn | n.a. | n.a. |
| Q4 2022 | 12 | $3.0bn | n.a. | n.a. |
| Q1 2023 | 9 | $2.6bn | n.a. | n.a. |
| Q2 2023 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2023 | 8 | $2.0bn | n.a. | n.a. |
| Q4 2023 | 11 | $2.8bn | 5 | 7 |
| Q1 2024 | 16 | $3.4bn | 10 | 6 |
| Q2 2024 | 14 | $2.8bn | 8 | 7 |
| Q3 2024 | 15 | $3.1bn | 11 | 5 |
| Q4 2024 | 11 | $2.6bn | 6 | 7 |
| Q1 2025 | 13 | $3.2bn | 7 | 6 |
| Q2 2025 | 11 | $3.2bn | 5 | 6 |
| Q3 2025 | 15 | $3.7bn | 6 | 8 |
| Q4 2025 | 14 | $3.7bn | 16 | 14 |
| Q1 2026 | 10 | $3.1bn | 7 | 25 |
| Q2 2026 | 12 | $4.3bn | 19 | 9 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ASND and LLY →ASND and JNJ →ASND and VRTX →Choose a stock to compare with ASND →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ASND, latest filings →Back to the 13F Explorer →